Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 1/20 | 0.59 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21316832 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887786 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5982137 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2922785 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887635 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL13030268 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887788 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL535680 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL15457036 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL12883747 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260036577-A1 | SANDWICH ASSAYS IN DROPLETS | BIO-RAD LABORATORIES, INC. | 2026-02-05 | — | — | US | disclosed |
| US-20250257391-A1 | ROLLING CIRCLE AMPLIFICATION COMPRISING CROSSLINKING AND DE-CROSSLINKING | 10X GENOMICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-12359197-B2 | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | ETAGEN PHARMA, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12292440-B2 | Sandwich assays in droplets | BIO-RAD LABORATORIES, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025042899-A2 | METHODS FOR IDENTIFYING COMPOUNDS BINDING TO A TARGET MOLECULE USING MIRROR-IMAGING OF THE TARGET MOLECULE | X-CHEM, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240384330-A1 | COVALENTLY LINKED BRANCHED DNA STRUCTURES AND USES THEREOF | 10X GENOMICS SWEDEN AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-20240280569-A1 | SANDWICH ASSAYS IN DROPLETS | BIO-RAD LABORATORIES, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4372091-A2 | COMPOSITIONS AND METHODS FOR EDITING NUCLEIC ACIDS IN CELLS UTILIZING OLIGONUCLEOTIDES | Woolf, Tod M. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-1956089-B1 | METHOD FOR DETECTING TARGET NUCLEIC ACID WITH SPECIFIC BASE SEQUENCE AND SET OF NUCLEIC ACIDS FOR DETECTION | JAPAN SCIENCE & TECH AGENCY (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2011020198-A1 | DNA LIGANDS FOR AFLATOXIN AND ZEARALENONE | NEOVENTURES BIOTECHNOLOGY LIMITED (CA) | 2011-02-24 | — | — | WO | disclosed |
| US-7851159-B2 | Method for detecting target nucleic acid with specific base sequence and set of nucleic acids for detection | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-12-14 | — | — | US | disclosed |
| EP-2242761-A1 | METHOD OF MYCOTOXIN DETECTION | Neoventures Biotechnology Inc. (CA) | 2010-10-27 | — | — | EP | disclosed |
| US-20090221429-A1 | Method for Detecting Target Nucleic Acid with Specific Base Sequence and Set of Nucleic Acids for Detection | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-09-03 | — | — | US | disclosed |
| WO-2009086621-A1 | METHOD OF MYCOTOXIN DETECTION | NEOVENTURES BIOTECHNOLOGY INC. (CA) | 2009-07-16 | — | — | WO | disclosed |
| EP-1956089-A1 | METHOD FOR DETECTING TARGET NUCLEIC ACID WITH SPECIFIC BASE SEQUENCE AND SET OF NUCLEIC ACIDS FOR DETECTION | Japan Science and Technology Agency (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20050147973-A1 | Immobilized probes | GE HEALTHCARE UK LIMITED (GB) | 2005-07-07 | — | — | US | disclosed |
| EP-1520038-A2 | DETECTION OF CIRCULARIZED IMMOBILIZED NUCLEIC ACID PROBES | Amersham Biosciences UK Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2003083137-A2 | DETECTION OF CIRCULARIZED IMMOBILIZED NUCLEIC ACID PROBES | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | TK1 472/4885CYP1A2 4471/4885CYP3A4 3959/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | TK1 1713/4885CYP1A2 1193/4885CYP3A4 987/4885 |
| US-20260036577-A1 | SANDWICH ASSAYS IN DROPLETS | DIS3, S100A4, CHMP4B | TK1 2552/4885CYP1A2 4327/4885CYP3A4 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.